ID: MRFR/Pharma/5435-HCR | February 2021 | Region: Global | 90 pages
Market Scenario:
Global Chronic Lymphocytic Leukemia (CLL) Treatment Market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 7.9 Billion in 2017 and is projected to grow at a CAGR of 19% over the forecast period. Chronic Lymphocytic Leukemia is a type of cancer that affects a specific type of white blood cell known as lymphocyte.
The factors such as rising prevalence of leukemia as well as CLL, increasing research & development activities and technological advancements related to the treatment are expected to propel the growth of the market. However, the high cost of treatment and stringent government regulations can hamper the market growth over the forecast period.
Segmentation:
The Global Chronic Lymphocytic Leukemia Treatment Market has been segmented into type, treatment and end user. The market, on the basis of type, has been segmented into indolent CLL and aggressive CLL.
The market, by treatment, has been segmented into chemotherapy, targeted drug therapy, immunotherapy and bone marrow transplant.
The market, by end user, has been segmented into hospitals & clinics, diagnostic laboratories, research institutes and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The chronic lymphocytic leukemia treatment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European chronic lymphocytic leukemia treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The chronic lymphocytic leukemia treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The chronic lymphocytic leukemia treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key players:
F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, CELGENE CORPORATION, Genmab A/S, Teva Pharmaceutical Industries Ltd., Genentech, Inc., Genzyme Corporation, AbbVie Inc., Gilead, Novartis AG, Johnson & Johnson Services, Inc., AstraZeneca, ONO PHARMACEUTICAL CO., LTD., TG Therapeutics, Inc., Ziopharm Oncology, Inc. and others are some of the key players in the global chronic lymphocytic leukemia treatment market.
Regional Market Summary:
Global Chronic Lymphocytic Leukemia Treatment Market Share (%), by Region, 2017
Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, Annual Reports
Geographically, the Americas is anticipated to dominate the global chronic lymphocytic leukemia treatment market owing to rising prevalence of leukemia and presence of major market players. According to a report published by the Leukemia & Lymphoma Society in 2018, every 3 minutes one person in the US is diagnosed with blood cancer (leukemia).
Europe is expected to hold the second largest position in the global chronic lymphocytic leukemia treatment market. The market growth in this region is attributed to rising research and development activities in the field of leukemia. The chronic lymphocytic leukemia treatment market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the rising prevalence of leukemia and growing demand for treatment of the disease. According to a report published by the World Health Organization in 2017, 8,904 leukemia deaths were reported in Japan.
The Middle East & Africa are expected to hold the least share of the market. The market growth in this region is expected to be driven by a developing healthcare infrastructure.
Global Chronic Lymphocytic Leukemia Treatment Market, by Type:
Global Chronic Lymphocytic Leukemia Treatment Market, by Treatment:
Global Chronic Lymphocytic Leukemia Treatment Market, by End User:
Global Chronic Lymphocytic Leukemia Treatment Market, by Region:
Global Chronic Lymphocytic Leukemia Treatment Market, by Key Players:
Intended Audience:
Frequently Asked Questions (FAQ) :
Chronic Lymphocytic Leukemia Treatment Market had a valuation of USD 7.9 billion in 2017.
Chronic Lymphocytic Leukemia Treatment Market would record a CAGR of 19% during the forecast period of 2018 to 2023.
Chronic Lymphocytic Leukemia Treatment Market would have end users like research institutes, diagnostic laboratories, hospitals & clinics, and others.
Chronic Lymphocytic Leukemia Treatment Market has been discussed on the basis of treatments like targeted drug therapy, chemotherapy, immunotherapy, and bone marrow transplant.
Americas are leading the Chronic Lymphocytic Leukemia Treatment Market.
Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Equipment Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Type
6.1 Introduction
6.2 Indolent CLL
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
6.3 Aggressive CLL
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
Chapter 7. Global Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Treatment
7.1 Introduction
7.2 Chemotherapy
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
7.3 Targeted Drug Therapy
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
7.4 Immunotherapy
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
7.5 Bone Marrow Transplant
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
Chapter 8. Global Chronic Lymphocytic Leukemia Treatment (CLL) Market, by End User
8.1 Introduction
8.2 Hospitals and Clinics
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
8.3 Diagnostic Laboratories
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
8.4 Research Institutes
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
8.5 Others
Market Estimates & Forecast, by Region, 2018–2023
Market Estimates & Forecast, by Country, 2018–2023
Chapter 9. Global Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Region
9.1 Introduction
9.2 Americas
9.2.1North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia-Pacific
9.5 Middle East & Africa
9.5.1 Middle East
9.5.2 Africa
Chapter 10. Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
Chapter 11. Company Profiles
11.1 F. Hoffmann-La Roche Ltd
11.1.1 Company Overview
11.1.2 Type Overview
11.1.3 Financials Overview
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.2 GlaxoSmithKline plc
11.2.1 Company Overview
11.2.2 Type Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 CELGENE CORPORATION
11.3.1 Company Overview
11.3.2 Type Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Genmab A/S
11.4.1 Company Overview
11.4.2 Type Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 Teva Pharmaceutical Industries Ltd.
11.5.1 Company Overview
11.5.2 Type Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.6 Genentech, Inc.
11.6.1 Company Overview
11.6.2 Type Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.7 Genzyme Corporation
11.7.1 Overview
11.7.2 Type Overview
11.7.3 Financial Overview
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 AbbVie Inc.
11.8.1 Overview
11.8.2 Type Overview
11.8.3 Financials
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.9 Gilead
11.9.1 Overview
11.9.2 Type Overview
11.9.3 Financials
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.10 Novartis AG
11.10.1 Overview
11.10.2 Type Overview
11.10.3 Financials
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.11 Johnson & Johnson Services, Inc.
11.11.1 Overview
11.11.2 Type Overview
11.11.3 Financials
11.11.4 Key Developments
11.11.5 SWOT Analysis
11.12 AstraZeneca
11.12.1 Overview
11.12.2 Type Overview
11.12.3 Financials
11.12.4 Key Developments
11.12.5 SWOT Analysis
11.13 ONO PHARMACEUTICAL CO., LTD.
11.13.1 Overview
11.13.2 Type Overview
11.13.3 Financials
11.13.4 Key Developments
11.13.5 SWOT Analysis
11.14 TG TREATMENT, INC.
11.14.1 Overview
11.14.2 Type Overview
11.14.3 Financials
11.14.4 Key Developments
11.14.5 SWOT Analysis
11.15 ZIOPHARM ONCOLOGY, INC.
11.15.1 Overview
11.15.2 Type Overview
11.15.3 Financials
11.15.4 Key Developments
11.15.5 SWOT Analysis
Chapter 12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Predictions for the Chronic Lymphocytic Leukemia Treatment (CLL) Industry
Chapter 13. Appendix
LIST OF TABLES:
Table 1 Global Chronic Lymphocytic Leukemia Treatment (CLL) Market Synopsis, 2018–2023
Table 2 Global Chronic Lymphocytic Leukemia Treatment (CLL) Market Estimates and Forecast, 2018–2023 (USD Million)
Table 3 Global Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Region, 2018–2023(USD Million)
Table 4 Global Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Type, 2018–2023 (USD Million)
Table 5 Global Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Treatment, 2018–2023 (USD Million)
Table 6 Global Chronic Lymphocytic Leukemia Treatment (CLL) Market, by End User, 2 018–2023 (USD Million)
Table 7 North America: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Type, 2018–2023 (USD Million) Table 8 North America: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Treatment, 2018–2023 (USD Million)
Table 9 North America: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by End User, 2018–2023 (USD Million)
Table 10US: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Type, 2018–2023(USD Million)
Table 11US: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Treatment, 2018–2023(USD Million)
Table 12 US: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by End User, 2018–2023(USD Million)
Table 13Canada: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Type, 2018–2023(USD Million)
Table 14Canada: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Treatment, 2018–2023 (USD Million)
Table 15Canada: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by End User, 2018–2023 (USD Million)
Table 16South America: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Type, 2018–2023 (USD Million)
Table 17South America: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Treatment, 2018–2023 (USD Million)
Table 18South America: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by End User, 2018–2023 (USD Million)
Table 19Europe: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Type, 2018–2023(USD Million)
Table 20Europe: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Treatment, 2018–2023 (USD Million)
Table 21Europe: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by End User, 2018–2023 (USD Million)
Table 22Western Europe: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Type, 2018–2023 (USD Million) Table 23 Western Europe: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Treatment, 2018–2023 (USD Million) Table 24Western Europe: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by End User, 2018–2023 (USD Million)
Table 25 Eastern Europe: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Type, 2018–2023 (USD Million) Table 26 Eastern Europe: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Treatment, 2018–2023 (USD Million) Table 27 Eastern Europe: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by End User, 2018–2023 (USD Million)
Table 28 Asia-Pacific: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Type,2018–2023 (USD Million) Table 29 Asia-Pacific: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Treatment, 2018–2023 (USD Million) Table 30 Asia-Pacific: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by End User, 2018–2023 (USD Million)
Table 31 Middle East & Africa: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Type, 2018–2023 (USD Million) Table 32 Middle East & Africa: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Treatment, 2018–2023 (USD Million) Table 33 Middle East & Africa: Chronic Lymphocytic Leukemia Treatment (CLL) Market, by End User, 2018–2023 (USD Million) LIST OF FIGURES:
Figure 1 Research Process
Figure 2 Market Structure for Global Chronic Lymphocytic Leukemia Treatment (CLL) Market
Figure 3 Market Dynamics for Global Chronic Lymphocytic Leukemia Treatment (CLL) Market
Figure 4 Global Chronic Lymphocytic Leukemia Treatment (CLL) Market Share, by Type, 2017
Figure 5 Global Chronic Lymphocytic Leukemia Treatment (CLL) Market Share, by Treatment, 2017
Figure 6 Global Chronic Lymphocytic Leukemia Treatment (CLL) Market Share, by End User, 2017
Figure 7 Global Chronic Lymphocytic Leukemia Treatment (CLL) Market Share, by Distribution Channel, 2017
Figure 8 Global Chronic Lymphocytic Leukemia Treatment (CLL) Market Share, by Region, 2017
Figure 9 North America: Chronic Lymphocytic Leukemia Treatment (CLL) Market Share, by Country, 2017
Figure 10 Europe: Chronic Lymphocytic Leukemia Treatment (CLL) Market Share, by Country, 2017
Figure 11 Asia-Pacific: Chronic Lymphocytic Leukemia Treatment (CLL) Market Share, by Country, 2017
Figure 12 Middle East & Africa: Chronic Lymphocytic Leukemia Treatment (CLL) Market Share, by Country, 2017
Figure 13 Global Chronic Lymphocytic Leukemia Treatment (CLL) Market: Company Share Analysis, 2017 (%)
Figure 14 F. Hoffmann-La Roche Ltd: Key Financials
Figure 15 F. Hoffmann-La Roche Ltd: Segmental Revenue
Figure 16 F. Hoffmann-La Roche Ltd: Geographical Revenue
Figure 17 GlaxoSmithKline plc: Key Financials
Figure 18 GlaxoSmithKline plc: Segmental Revenue
Figure 19 GlaxoSmithKline plc: Geographical Revenue
Figure 20 CELGENE CORPORATION: Key Financials
Figure 21 CELGENE CORPORATION: Segmental Revenue
Figure 22 CELGENE CORPORATION: Geographical Revenue
Figure 23 Genmab A/S: Key Financials
Figure 24 Genmab A/S: Segmental Revenue
Figure 25 Genmab A/S: Geographical Revenue
Figure 26 Teva Pharmaceutical Industries Ltd.: Key Financials
Figure 27 Teva Pharmaceutical Industries Ltd.: Segmental Revenue
Figure 28 Teva Pharmaceutical Industries Ltd.: Geographical Revenue
Figure 29 Genentech, Inc.: Key Financials
Figure 30 Genentech, Inc.: Segmental Revenue
Figure 31 Genentech, Inc.: Geographical Revenue
Figure 32 Genzyme Corporation: Key Financials
Figure 33 Genzyme Corporation: Segmental Revenue
Figure 34 Genzyme Corporation: Geographical Revenue
Figure 35 AbbVie Inc.: Key Financials
Figure 36 AbbVie Inc.: Segmental Revenue
Figure 37 AbbVie Inc.: Geographical Revenue
Figure 38 Gilead: Key Financials
Figure 39 Gilead: Segmental Revenue
Figure 40 Gilead: Geographical Revenue
Figure 41 Novartis AG: Key Financials
Figure 42 Novartis AG: Segmental Revenue
Figure 43 Novartis AG: Geographical Revenue
Figure 44 Johnson & Johnson Services, Inc.: Key Financials
Figure 45 Johnson & Johnson Services, Inc.: Segmental Revenue
Figure 46 Johnson & Johnson Services, Inc.: Geographical Revenue
Figure 47 AstraZeneca: Key Financials
Figure 48 AstraZeneca: Segmental Revenue
Figure 49 AstraZeneca: Geographical Revenue
Figure 50 ONO PHARMACEUTICAL CO., LTD.: Key Financials
Figure 51 ONO PHARMACEUTICAL CO., LTD.: Segmental Revenue
Figure 52 ONO PHARMACEUTICAL CO., LTD.: Geographical Revenue
Figure 53 TG TREATMENT, INC.: Key Financials
Figure 54 TG TREATMENT, INC.: Segmental Revenue
Figure 55 TG TREATMENT, INC.: Geographical Revenue
Figure 56 ZIOPHARM ONCOLOGY, INC.: Key Financials
Figure 57 ZIOPHARM ONCOLOGY, INC.: Segmental Revenue
Figure 58 ZIOPHARM ONCOLOGY, INC.: Geographical Revenue